
Loading, please wait...

Loading, please wait...

A systematic review and meta-analysis examined active fluid de-resuscitation strategies in patients with septic shock, including diuretics and active fluid removal. The review included 13 studies, with five randomised controlled trials contributing to the quantitative analysis. The evidence did not show a mortality benefit from active de-resuscitation compared with usual care. Although some studies achieved greater fluid separation, patient-centred outcomes were generally unchanged, and the evidence base was limited by small samples and heterogeneity in the interventions used. The paper is highly relevant to CritiCARE's focus on de-resuscitation and fluid stewardship. It reinforces a key distinction: reducing a patient's fluid balance is not automatically the same as improving survival. For clinicians, active fluid removal should therefore be linked to an identifiable clinical problem such as fluid overload, venous congestion or failure to tolerate additional fluid—not simply to a desire to make the balance more negative. The practical approach is phase-based resuscitation: give fluid when there is a clear indication, reassess whether the patient remains fluid responsive, and consider fluid removal once the haemodynamic objective has been achieved and congestion becomes harmful. The review supports careful, patient-specific de-resuscitation while highlighting the need for better randomised evidence.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A systematic review and meta-analysis examined active fluid de-resuscitation strategies in patients with septic shock, including diuretics and active fluid removal. The review included 13 studies, with five randomised controlled trials contributing to the quantitative analysis. The evidence did not show a mortality benefit from active de-resuscitation compared with usual care. Although some studies achieved greater fluid separation, patient-centred outcomes were generally unchanged, and the evidence base was limited by small samples and heterogeneity in the interventions used. The paper is highly relevant to CritiCARE's focus on de-resuscitation and fluid stewardship. It reinforces a key distinction: reducing a patient's fluid balance is not automatically the same as improving survival. For clinicians, active fluid removal should therefore be linked to an identifiable clinical problem such as fluid overload, venous congestion or failure to tolerate additional fluid—not simply to a desire to make the balance more negative. The practical approach is phase-based resuscitation: give fluid when there is a clear indication, reassess whether the patient remains fluid responsive, and consider fluid removal once the haemodynamic objective has been achieved and congestion becomes harmful. The review supports careful, patient-specific de-resuscitation while highlighting the need for better randomised evidence.
Today

The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back

A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back

Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back

A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back

A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back